Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the acquisition of rights to two preclinical-stage AAV-based gene… Read More »Opus Genetics Inc., has announced the acquisition of rights to two preclinical-stage for inherited retinal diseases (IRDs) from Iveric Bio (NASDAQ: ISEE)
Researchers, clinicians and patients & families are to support a workshop in La Jolla, San Diego (March 29th-31st) for those focused on finding treatments on… Read More »A Peripherin 2 (Prph2) retinal disease workshop is scheduled with international researchers, clinicians and patients, supported by Foundation Fighting Blindness
Researchers at the Institute of Mathematics, Kassel University and the Department of Ophthalmology, Heidelberg University, have reported a novel in silico model and algorithm for… Read More »A novel in silico model and algorithm for refining therapeutic treatment of retinal disease
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the March 8th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »March 8th, 2023 “EURETINA-Brief”© Issue No. 267
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) has announced that the U.S. Food and Drug Administration (FDA) has approved pegcetacoplan injection (labelled “SYFOVRE”), for the treatment of… Read More »Apellis Pharmaceuticals announce the approval of pegcetacoplan injection for the treatment of geographic atrophy (GA).
Researchers have announced recruitment of the first patient in a clinical trial of a an experimental AAV gene therapy for the treatment of X-linked retinitis… Read More »A phase I/II study has announced the recruitment of the first patient for a novel AAV-RPGR treatment for X-linked retinitis pigmentosa.
Researchers at the Department of Ophthalmology, Medical University Graz, Austria and the Department of Ophthalmology, University of Basel, Switzerland, have reported that fundus auto-fluorescence (FAF)… Read More »Fundus autofluorescence assessment tracks Stargardt disease progression for a 24-month period.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the February 19th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »February 19th, 2023 “EURETINA-Brief”© Issue No. 266
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), based in Paris, France, have announced the publication of updated efficacy results from a pooled analysis of… Read More »GenSight Biologics announces a pooled presentation of LUMEVOQ versus natural history in ND4-LHON.
Researchers at the Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, have reported that outcome measures for future clinical trials should include evaluations… Read More »Outcome measures for future trials for autosomal dominant vitelliform macular dystrophy caused by BEST1 mutations.